PDE6D

Across TCGA pan-cancer cohorts, PDE6D RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated PDE6D data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PDE6D RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDE6D expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

ACC, BLCA, and MESO are the cancer types where PDE6D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.241	0.693	<.001	105	view →
BLCA	OS	Median	III,IV	0.515	0.273	<.001	52	view →
MESO	OS	Median	All	0.432	0.664	.001	48	view →
KIRP	OS	Quartile	All	0.779	0.949	.001	43	view →
READ	OS	Median	All	0.578	0.797	.003	36	view →
UCS	OS	Tertile	IV	0.241	0.844	.024	30	view →
LUSC	DFS	Tertile	III,IV	0.493	0.818	.003	25	view →
CHOL	DFS	Median	II,III,IV	0.104	0.568	.002	17	view →
STAD	DFS	Median	All	0.616	0.455	.004	14	view →
KIRC	DFS	Median	All	0.916	0.807	.027	14	view →
KICH	DFS	Tertile	III,IV	0.511	1.000	.018	14	view →
UCEC	DFS	Quartile	All	0.470	0.736	.015	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

PDE6D–ACC (DFS)

Open the ACC breakdown →